Pepper Hamilton Sample Contracts

Share Cite Term
Link

Embed (HTML)
93658691v1 (October 17th, 2017)
CREDIT AGREEMENT Dated as of October 5, 2017 Among UNISYS CORPORATION the Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent (October 6th, 2017)

CREDIT AGREEMENT dated as of October 5, 2017 (as it may be amended or modified from time to time, this "Agreement") among UNISYS CORPORATION, as Borrower, the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

Nuvilex Inc – Indenture (September 13th, 2017)

WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities ("Securities"), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;

Nuvilex Inc – Indenture (September 13th, 2017)

WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities ("Securities"), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;

Discovery Laboratories, Inc. – LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and Between Windtree Therapeutics, Inc. And Lee's Pharmaceutical (Hk) LTD. (August 21st, 2017)

This License, Development and Commercialization Agreement (this "Agreement") is entered into as of June 12, 2017 (the "Effective Date"), by and between Windtree Therapeutics, Inc., a Delaware corporation with its principal offices at 2600 Kelly Rd., Suite 100, Warrington, PA 18976 ("Licensor"), and Lee's Pharmaceutical (HK) Ltd., a Hong Kong company organized and existing under the laws of Hong Kong with its principal offices at Unit 110-111, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong ("Licensee"). Licensor and Licensee are sometimes referred to in this Agreement individually as a "Party" and together as the "Parties."

Medgenics Inc – Form of Securities Purchase Agreement (August 11th, 2017)

This Securities Purchase Agreement (this "Agreement") is dated as of [____], 2017 by and among Aevi Genomic Medicine, Inc., a Delaware corporation (the "Company"), and each purchaser listed on Schedule A attached hereto (each, including its successors and assigns, a "Purchaser" and collectively, the "Purchasers").

Sito Mobile, Ltd. – July 28, 2017 (July 28th, 2017)
Securities Purchase Agreement (July 6th, 2017)

This Securities Purchase Agreement (this Agreement), dated as of July 6, 2017, for the purchase and sale of all of the outstanding shares of Pacific Foods of Oregon, Inc., an Oregon corporation (the Company), is entered into by and among the Company, the shareholders of the Company set forth on Schedule 2.01 (each a Shareholder and collectively, the Shareholders), PFO Shareholders Corp., an Oregon corporation and Affiliate of the Company (the Seller), Campbell Investment Company, a Delaware corporation (Buyer), and Charles W. Eggert, an individual in his capacity as the Shareholder Representative.

Interpace Diagnostics Group, Inc. Underwriting Agreement (June 21st, 2017)
Interpace Diagnostics Group, Inc. Underwriting Agreement (June 13th, 2017)
Global Partner Acquisition Corp. – Re: Merger Agreement Dated January 11, 2017 (May 22nd, 2017)

Pursuant to Section 8.1(b) of the above-referenced Merger Agreement between and among Global Partner Acquisition Corp., Global Partner Sponsor I LLC, Sequel Acquisition, LLC, Sequel Youth and Family Services, LLC, the Key Equityholders (as defined in such Merger Agreement) and John F. Ripley, the undersigned, on behalf of Sequel Youth and Family Services, LLC, does hereby terminate the Merger Agreement, effective immediately.

Applied DNA Sciences – Indenture (May 22nd, 2017)

INDENTURE, dated as of [*], 20[*], among APPLIED DNA SCIENCES, INC., a Delaware corporation (the "Company"), and [TRUSTEE], as trustee (the "Trustee").

Applied DNA Sciences – Indenture (May 22nd, 2017)

INDENTURE, dated as of [*], 20[*], among APPLIED DNA SCIENCES, INC., a Delaware corporation (the "Company"), and [TRUSTEE], as trustee (the "Trustee").

FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT by and Between FIVE BELOW, INC., as Borrower, and FIVE BELOW MERCHANDISING, INC., as Original Guarantor, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Lender Dated: May 10, 2017 (May 11th, 2017)

This Fourth Amended and Restated Loan and Security Agreement dated May 10, 2017 (this Agreement) is entered into by and between FIVE BELOW, INC., a Pennsylvania corporation (the Borrower), FIVE BELOW MERCHANDISING, INC., a Pennsylvania corporation (the Original Guarantor), and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as successor by merger to Wachovia Bank, N.A. (the Lender).

Otelco, Inc. – Amendment No. 2 to Subordinated Loan Agreement (May 4th, 2017)

AMENDMENT NO. 2 TO SUBORDINATED LOAN AGREEMENT dated as of April 4, 2017 (this "Amendment"), to the Subordinated Loan Agreement, dated as of January 25, 2016 (as amended by that certain Amendment No. 1 to Subordinated Loan Agreement, dated February 17, 2016, and as otherwise amended, restated or otherwise modified from time to time, the "Loan Agreement"), by and among Otelco Inc., a Delaware corporation (the "Parent"), each subsidiary of the Parent listed as a "Borrower" on the signature pages thereto (together with Parent and each other Person that executes a joinder agreement and becomes a "Borrower" thereunder, collectively, the "Borrowers" and each, a "Borrower"), the investors from time to time party thereto (each an "Investor" and collectively, the "Investors"), NewSpring Mezzanine Capital III, L.P., a Delaware limited partnership ("NewSpring"), as collateral agent for the Investors (in such capacity, together with its successors and assigns in such capacity, the "Agent"). All te

Amendment and Exchange Agreement (April 18th, 2017)

This Amendment and Exchange Agreement (this "Agreement") is made as of the __th day of April, 2017 by and between, Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company") and the holder identified on the signature page hereto ("Investor"). Capitalized terms not defined herein shall have the meaning as set forth in the Initial Exchange Agreement (as defined below).

Axovant Sciences Ltd. – 6,742,179 Common Shares Axovant Sciences Ltd. UNDERWRITING AGREEMENT (April 13th, 2017)
VISHAY PRECISION GROUP, INC. 3 Great Valley Parkway Malvern, Pennsylvania 19355 (March 27th, 2017)

This letter (this "Agreement") constitutes the agreement between Vishay Precision Group, Inc. (the "Company"), on the one hand, and Nokomis Capital, L.L.C. ("Nokomis") and each of the other related Persons (as defined below) set forth on the signature pages to this Agreement (collectively with Nokomis, the "Nokomis Group"), on the other hand. The Nokomis Group and its Affiliates (as defined below) and Associates (as defined below) are collectively referred to as the "Investors."

Common Stock Purchase Warrant Interpace Diagnostics Group, Inc. (March 27th, 2017)

THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, RedPath Equityholder Representative, LLC, a Delaware limited liability company, or its assigns, (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 22, 2017 (the "Initial Exercise Date") and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company"), up to _______________ shares (as subject to adjustment hereunder, the "Warrant Shares") of common stock of the Company, par value $.01 per share (the "Common Stock"). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Common Stock Purchase Warrant Interpace Diagnostics Group, Inc. (March 23rd, 2017)

THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, RedPath Equityholder Representative, LLC, a Delaware limited liability company, or its assigns, (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2017 (the "Initial Exercise Date") and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company"), up to _______________ shares (as subject to adjustment hereunder, the "Warrant Shares") of common stock of the Company, par value $.01 per share (the "Common Stock"). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Exchange Agreement (March 23rd, 2017)

This Exchange Agreement (this "Agreement") is made as of the 22nd day of March 2017, by and between, Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company") and the holder identified on the signature page hereto ("Investor"). Capitalized terms not defined herein shall have the meaning as set forth in the Exchanged Notes (as defined below).

ASSET PURCHASE AGREEMENT by and Between INFOR (US), INC. And CIBER, INC. Dated as of March 20, 2017 (March 21st, 2017)

THIS ASSET PURCHASE AGREEMENT (this Agreement), dated as of March 20, 2017 (the Effective Date), is entered into by and between Ciber, Inc., a Delaware corporation (Seller), and Infor (US), Inc., a Delaware corporation (Buyer). Seller and Buyer sometimes are referred to in this Agreement collectively as the Parties and each individually as a Party.

Tranche 1 Promissory Note (February 8th, 2017)

THIS DOCUMENT IS THE "PROMISSORY NOTE" AS DEFINED IN THE SUBORDINATION AGREEMENT DATED AS OF THE DATE HEREOF (THE "SUBORDINATION AGREEMENT"), BY AND AMONG TC LENDING, LLC, AS SENIOR CREDITOR (AS DEFINED IN THE SUBORDINATION AGREEMENT), ACQUIRER (AS DEFINED BELOW) AND HOLDER (AS DEFINED BELOW), WHICH PROVIDES FOR, AMONG OTHER THINGS, THE SUBORDINATION OF THIS DOCUMENT AND ANY RIGHT OF PAYMENT HEREUNDER TO THE OBLIGATIONS OF ACQUIRER TO THE SENIOR CREDITOR UNDER THE SENIOR DEBT (AS DEFINED IN THE SUBORDINATION AGREEMENT). ENFORCEMENT OF THIS NOTE AND PAYMENT OF THIS NOTE ARE SUBJECT TO THE SUBORDINATION AGREEMENT. IF THERE IS ANY CONFLICT BETWEEN THE TERMS OF THIS NOTE AND THE TERMS OF THE SUBORDINATION AGREEMENT, THE TERMS OF THE SUBORDINATION AGREEMENT SHALL CONTROL IN ALL RESPECTS.

Tranche 2 Promissory Note (February 8th, 2017)

THIS DOCUMENT IS THE "PROMISSORY NOTE" AS DEFINED IN THE SUBORDINATION AGREEMENT DATED AS OF THE DATE HEREOF (THE "SUBORDINATION AGREEMENT"), BY AND AMONG TC LENDING, LLC, AS SENIOR CREDITOR (AS DEFINED IN THE SUBORDINATION AGREEMENT), ACQUIRER (AS DEFINED BELOW) AND HOLDER (AS DEFINED BELOW), WHICH PROVIDES FOR, AMONG OTHER THINGS, THE SUBORDINATION OF THIS DOCUMENT AND ANY RIGHT OF PAYMENT HEREUNDER TO THE OBLIGATIONS OF ACQUIRER TO THE SENIOR CREDITOR UNDER THE SENIOR DEBT (AS DEFINED IN THE SUBORDINATION AGREEMENT). ENFORCEMENT OF THIS NOTE AND PAYMENT OF THIS NOTE ARE SUBJECT TO THE SUBORDINATION AGREEMENT. IF THERE IS ANY CONFLICT BETWEEN THE TERMS OF THIS NOTE AND THE TERMS OF THE SUBORDINATION AGREEMENT, THE TERMS OF THE SUBORDINATION AGREEMENT SHALL CONTROL IN ALL RESPECTS.

Underwriting Agreement (February 3rd, 2017)

This Underwriting Agreement (this "Agreement") is dated as of February 3, 2017, between Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company"), and the several underwriters (such underwriters, for whom Maxim Group LLC ("Maxim" or the "Representative") is acting as representative, the "Underwriters" and each an "Underwriter").

Securities Purchase Agreement (January 20th, 2017)

This Securities Purchase Agreement (this "Agreement") is dated as of January 20, 2017, between Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively the "Purchasers").

Global Partner Acquisition Corp. – AGREEMENT AND PLAN OF MERGER BY AND AMONG Global Partner Acquisition COrp. Global Partner Sponsor I LLC SEQUEL ACQUISITION, Llc Sequel Youth and Family Services, LLC KEY EQUITYHOLDERS AND SECURITYHOLDER REPRESENTATIVE (January 18th, 2017)

THIS AGREEMENT AND PLAN OF MERGER (the "Agreement") is made and entered into as of January 11, 2017 by and among Global Partner Acquisition Corp., a Delaware corporation ("Parent"); Global Partner Sponsor I LLC, a Delaware limited liability company and a stockholder of Parent ("Sponsor"); Sequel Acquisition, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent ("Sub"); Sequel Youth and Family Services, LLC, an Iowa limited liability company (the "Company"); the Key Equityholders; and John F. Ripley, who will serve as the representative of the Company's Legacy Equityholders and is referred to herein from time to time as the "Securityholder Representative".

Sales Agency Financing Agreement (January 10th, 2017)

Sales Agency Financing Agreement (this Agreement), dated as of January 10, 2017 between BRANDYWINE REALTY TRUST, a Maryland real estate investment trust (the Company) and BRANDYWINE OPERATING PARTNERSHIP, L.P., a Delaware limited partnership (the Operating Partnership), and RBC Capital Markets, LLC, a registered broker-dealer organized under the laws of Delaware (the Agent).

Sales Agency Financing Agreement (January 10th, 2017)

Sales Agency Financing Agreement (this Agreement), dated as of January 10, 2017 between BRANDYWINE REALTY TRUST, a Maryland real estate investment trust (the Company) and BRANDYWINE OPERATING PARTNERSHIP, L.P., a Delaware limited partnership (the Operating Partnership), and Barclays Capital Inc., a registered broker-dealer organized under the laws of Delaware (the Agent).

Sales Agency Financing Agreement (January 10th, 2017)

Sales Agency Financing Agreement (this Agreement), dated as of January 10, 2017 between BRANDYWINE REALTY TRUST, a Maryland real estate investment trust (the Company) and BRANDYWINE OPERATING PARTNERSHIP, L.P., a Delaware limited partnership (the Operating Partnership), and Jefferies LLC, a registered broker-dealer organized under the laws of Delaware (the Agent).

Sales Agency Financing Agreement (January 10th, 2017)

Sales Agency Financing Agreement (this Agreement), dated as of January 10, 2017 between BRANDYWINE REALTY TRUST, a Maryland real estate investment trust (the Company) and BRANDYWINE OPERATING PARTNERSHIP, L.P., a Delaware limited partnership (the Operating Partnership), and BNY Mellon Capital Markets, LLC, a registered broker-dealer organized under the laws of Delaware (the Agent).

Agreement and Plan of Merger (January 5th, 2017)

This Agreement and Plan of Merger (this "Agreement") is made and entered into as of December 12, 2016 (the "Agreement Date"), by and among Model N, Inc., a Delaware corporation ("Acquirer"), Nexus Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Acquirer ("Merger Sub"), Sapphire Stripe Holdings, Inc., a Delaware corporation (the "Company"), and LLR Equity Partners III, L.P., a Delaware limited partnership, as the stockholders' agent (the "Stockholders' Agent"). Certain other capitalized terms used herein are defined in Exhibit A.

International Tower Hill Min – INTERNATIONAL TOWER HILL MINES LTD. PAULSON & CO. INC. INVESTOR RIGHTS AGREEMENT December 28, 2016 (January 5th, 2017)

Section 1 GENERAL 1 1.1 Definitions 1 1.2 Recitals and Schedules 5 1.3 Headings 5 1.4 Gender and Number 6 1.5 Currency 6 Section 2 COMPOSITION AND BOARD MATTERS 6 2.1 Board Composition and Representation 6 2.2 Board Matters 8 2.3 Notice of Meetings 9 Section 3 PARTICIPATION RIGHT GRANTED BY THE CORPORATION 9 3.1 Exercise of Participation Right 9 3.2 Excluded Securities 11 Section 4 REGISTRATION RIGHTS 11 4.1 Demand Registration Rights 11 4.2 Piggyback Registration Rights 14 4.3 Expenses 15 4.4 Other Sales 15 4.5 Future Registration Rights 15 4.6 Preparation; Reasonable Investigation 15 4.7 Underwriting or Agency

Credit and Security Agreement (January 4th, 2017)

THIS CREDIT AND SECURITY AGREEMENT (the "Agreement") is made as of the 29th day of December, 2016, by and between (a) GSE SYSTEMS, INC., a Delaware corporation ("Parent"), and (b) GSE PERFORMANCE SOLUTIONS, INC., a Delaware corporation ("GSE Performance" and jointly and severally with Parent, the "Borrower"), and CITIZENS BANK, NATIONAL ASSOCIATION ("Bank"). Borrower and Bank agree, under seal, as follows:

Securities Purchase Agreement (January 3rd, 2017)

This Securities Purchase Agreement (this "Agreement") is dated as of January 3, 2017, between Interpace Diagnostics Group, Inc., a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively the "Purchasers").